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up-staged and 2 cases (5%) were down-staged. In patients with staging 
discrepancy, PET-staging was accurate in 8 cases including undetected 
M1 disease, and conventional staging was accurate in 3 cases, based 
on overdiagnosis of N factor by PET. Synchronous malignant diseases 
(laryngeal cancer and malignant lymphoma) were detected by PET. 
One bronchioloalveolar carcinoma showing focal ground-glass opacity 
on CT was PET negative. PET correctly identiﬁed surgical candidates 
in 13 of 42 cases. In resected cases, one false negative (6%) and 3 false 
positive (19%) lymph node metastases were diagnosed by PET. Since 
the false negative case was microscopic N2 limited to one station, 
curative operation was performed. If we considered PET cN3 disease 
as a surgical contraindication, one surgical candidate would have been 
denied surgery. Maximum standardized uptake value (maxSUV) of 
all primary lesions ranged from 0 to 23.0 (8.1±4.3, mean±SD). The 
maxSUV among surgical cases (6.3±3.5) was smaller than among 
nonsurgical cases (9.3±4.4, p<0.05). The maxSUV was similar among 
the different histologic types.
Conclusions: FDG-PET/CT is useful for determining the clinical stage 
and resectability of primary lung cancer. However, false positive ﬁnd-
ings in regional lymph nodes, possibly due to past infectious diseases, 
are of major concern to be solved. A negative PET study in lymph 
nodes and distant metastases suggests that these patients can proceed 
directly to thoracotomy without mediastinoscopy. The maxSUV was 
related with resectability of primary lung cancer.
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Background: RAD001 (everolimus) is a novel inhibitor of mTOR for-
mulated for oral administration, currently investigated as an anticancer 
agent in clinical studies. In preclinical experiments a prominent impact 
of mTOR inhibition on glucose homeostasis was described with the 
transcription factor HIF-1 as one of the primary mediators of RAD001-
induced inhibition of mTOR. Moreover, the inhibition of FDG uptake 
has been demonstrated by FDG-PET imaging in preclinical models 
treated with RAD001. Therefore we reasoned that glucose metabolism 
as measured by FDG-PET might thus serve as a pharmacodynamic 
marker of RAD001 acting on its target in cancer pts. Here we report for 
the ﬁrst time on the use of FDG-PET in evaluation of the pharmacody-
namic effects of RAD001 in pts with recurrent NSCLC.
Patients and Methods: Patients with advanced NSCLC previously 
treated with either chemotherapy only or with chemotherapy and an 
EGFR inhibitor were treated with 10 mg continuous daily dose of 
RAD001 in an open label, multi-centre phase II study. A subgroup of 8 
pts enrolled in 2 of the study centres was evaluated by serial FDG-PET 
scans. FDG-PET was performed at the baseline and on the day 8 of 
treatment in all 8 patients. In addition, in 5 out of these 8 pts FDG-PET 
was performed on the day 28 of treatment. Evaluation of FDG-PET 
scans was performed centrally. The sum of the maximum standardized 
uptake values (sSUVmax) measured in up to 5 lesions was calculated at 
each time point. Percentage change of sSUVmax values from base-
line was calculated on days 8 and 28. In addition, standard computed 
tomography (CT) scans obtained at baseline (8 pts) and on day 28 (6 
pts) were evaluated and the change of the sum of the longest diameter 
of lesions (up to 10 selected lesions including those evaluated by FDG-
PET) was calculated. A lesion by lesion analysis will be presented. 
Results: Reduction of sSUVmax on day 8 was observed in all pts and 
ranged between 1.4% and 89.1%. Reduction of sSUVmax on day 28 
was less pronounced compared to the reduction on day 8.
Changes in sSUVmax (day 8 and day 28) and changes in sums of 
longest diameter of lesions evaluated by CT scans are provided in table 
below.
Patient Change Change Change
Number
sSUVmax  
d8(%)
sSUVmax  
d28(%)
sumCT  
d28(%)
0701-0002 -19.4 1.5 3.3
0701-0003 -1.4 NA NA
0701-0004 -89.1 -82.3 -26.6
0701-0005 -19.2 NA NA
0601-0001 -52.2 -9.7 77.9
0601-0003 -17.4 NA 12.7
0601-0007 -13.0 -2.9 11.1
0601-0009 -20.6 -12.7 -16.7
NA=Not Available Measurements       
Conclusions: Results of this study suggest the value of FDG-PET as 
a tool for early evaluation of the pharmacodynamic effect of mTOR 
inhibitors such as RAD001 in patients with NSCLC. In addition, con-
ﬁrmation of similar results obtained in preclinical models suggests the 
usefulness of FDG-PET in clinical proﬁling of mTOR inhibitors.
Correlation of early pharmacodynamic changes evaluated by FDG-PET 
with clinical effects of RAD001 treatment should be evaluated in larger 
studies.
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Background: CT-guided Transthoracic Needle Aspiration Biopsy 
(TNAB) is widely used as a diagnostic tool in the diagnostic work-
up of thoracic lesions. The reported sensitivity for detection of lung 
neoplastic lesions with CT-guided TNB varies from 68% to 93% with 
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acceptable complication rates. The availability of a pathologist at the 
time of the procedure may ameliorate the sensitivity, reduce the number 
of biopsies and false negatives. Aim of this prospective study was to 
estimate the efﬁcacy of the procedure and to determine which factors 
affect its diagnostic accuracy.
Methods: From 11/2002 to 12/2006 655 patients with a CT-docu-
mented central or peripheral pulmonary lesion candidate for a FNAB 
were prospectively considered; 70% were males, median age was 66 
years (range 29-87). Ineligibility criteria for the FNAB included severe 
coagulopathy, previous controlateral pneumonectomy, lesions with 
a maximum diameter less than 5 mm or the impossibility to sign an 
informed consent or to maintain the clinostatic position for the time 
of the procedure. At the time of the FNAB the pathologist assigned to 
each specimen a semiquantitative score: 0 for bloody sample without 
other cells, 1 for aspeciﬁc benign or inﬂammatory cells, 2 for malig-
nant cells without histotype characterization and 3 for well established 
benign or malignant histotype. Factors known to affect diagnostic 
accuracy of CT-guided TNAB were also considered such as ﬁnal diag-
nosis (benign versus malignant), lesion size, lesion depth, presence of 
necrosis and cavitation in lung lesions, calciﬁcations, lesion morphol-
ogy and location, and occurrence of complications (pneumothorax and 
bleeding). All variables were analysed by Chi-square and Student t test 
for correct or incorrect diagnosis. A p value less than 0.05 considered 
statistically signiﬁcant.
Results: Most of the procedures was performed by FNAB, while in a 
minority of cases a tru-cut biopsy was requested. In 57.6% of the cases 
a single transthoracic access (range 1-4) was used and in 31% the pro-
cedure was repeated based on radiologist/pathologist judgment. In 174 
patients a surgical resection was subsequently performed, while 486 
patients were non-surgical. A score of 3 was obtained in 71% of cases 
(88% malignancies), 2 in 12.5%, 1 in 7.5% and 0 in 9%. A deﬁnitive 
diagnosis was made in 83.5% of procedures, while a score of 0-1 was 
assigned in 101 cases. Among 495 malignancies there were 446 lung 
cancers, 7 non-epithelial cancers and 42 metastases with only 1 false 
positive. The diagnostic accuracy for benign and malignant lesions 
was 67% and 92%, respectively (Pearson’s test p<0.005) with overall 
diagnostic accuracy of 83.3%. The variables affecting diagnostic ac-
curacy were ﬁnal diagnosis (benign 67%, malignant 92%, p < 0.001) 
and lesion size considered as the average lesion diameter in two axial 
planes (lesion < 1.5 cm 67%, 1.5-5.0 cm 87%, > 5 cm 78%, p < 0.05). 
The presence of cavitation or necrotic areas, lesion morphology and 
location, the presence of calciﬁcations, lesion depth and occurrence 
of complications during the procedure did not affect the diagnostic 
accuracy. 
Conclusion: In consecutive cases of CT-guided TNAB ﬁnal diagnosis 
and lesion size affect diagnostic accuracy.
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Background: The appearance of the speedup in MDCT (multidetector 
CT) have revolutionized the diagnostic approach to lung cancer. This 
technology enables continual wide scans in a short time. Thin-section 
computerized tomography (TS-CT) scans can depict ﬁne morpho-
logic characteristics of small peripheral lung cancers, which improves 
diagnosis. However, we are still troubled in differentiating between 
benign and malignant lesions. It is possible to reconstitute high resolu-
tion multi-planar reformation (MPR) images from TS-CT scans. The 
purpose of this study was to improve the qualitative diagnosis of small 
peripheral lung cancers. 
Methods: The subjects of our study included 159 cases (162 lesions), 
who underwent resection of small peripheral lung cancers (less than 
20mm in diameter) at Kanagawa Cancer Center between August 2002 
and June 2006. We examined preoperative TS-CT images (horizontal 
section) and MPR images (coronal sections, sagittal sections) preop-
eratively by Aquillion M/16 made by Toshiba. All cases involved ad-
enocarcinoma (Noguchi’s classiﬁcation: typeA 23, typeB 43, typeC 59, 
typeD 20, typeE 3, typeF 13, unknown 1).These cases were retrospec-
tively reviewed and a correlation between the TS-CT lesion images and 
the pathological ﬁndings (according to Noguchi’s classiﬁcation) were 
studied. All CT images were examined by an extended scale (window 
level:-600, window with:1600) and slice thickness of 0.5~1.0mm, using 
a 0.5~1.0mm scan. We examined the pertaining vascular, bronchial and 
marginal properties of the lesions.
Results: The MPR images revealed characteristic ﬁndings in 57% of 
the nodules, those of which included vascular involvement (56 lesions), 
and marginal properties (45 lesions). Additional ﬁndings were easy to 
obtain for lesions of the superior lobe (apex area). There were signiﬁ-
cantly more ﬁndings in type C, D, E, and F, according to Noguchi’s 
classiﬁcation, than in type A, and B. 
Conclusion: Evaluation in three dimensions was enabled by using 
MPR images (coronal section, sagittal section) in comparison with 
only using TS-CT images (horizontal sections). We concluded that 
evaluation of MPR images in addition to TS-CT scans taken in small 
peripheral adenocarcinoma of the lung improved the qualitative diag-
nostic probability of lung cancer, because these modalities provide ad-
ditional useful information pertaining to vascular, bronchial and pleural 
involvement, and the related marginal properties of lesions.
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Background: PNS are a heterogenous group of disorders in patients 
with malignancy. Often, these are the presenting symptoms of a malig-
nancy, most commonly lung cancers. Auto-antibodies against different 
neuronal antigens can be detected in the serum, however an underlying 
malignancy may be difﬁcult to identify. PET using 18-ﬂurodeoxygen-
ase glucose (18-FDG) has been employed to detect occult malignancy. 
We present the Mayo Clinic experience with PET in diagnosis of occult 
malignancy.
Methods: A single center retrospective chart review of all patients, 
who underwent PET with the diagnosis of suspected or proven parane-
oplastic syndrome from January 2000 to October 2006 at Mayo Clinic, 
Rochester. The PET scan report was considered positive if it showed 
any foci of increased 18-FDG uptake, as noted by the radiologist. A CT 
